Called Contrave, the new drug is the third prescription weight loss drug to be approved by the FDA since Contravean extended-release form of new weight loss pill previously approved drugs, naltrexone and bupropion, was approved in September Another clinical trial that included patients with type 2 diabetes found that patients had an average weight loss of almost 4 percent after one year. The most common side effects associated with Saxenda new fda approved weight loss pill nausea, diarrhea, constipation, vomiting, low blood sugar and loss of appetite. This content has not been reviewed within the past year and may not represent WebMD's most up-to-date information. Patients who experience a prolonged increase in their resting heart rate should stop taking Saxenda, the FDA added. In addition, their pills include a small portion of potassium for maximum absorption of HCA.
The agency on Tuesday approved Saxenda liraglutide for adults who are obese or for those who are overweight and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes or high cholesterol. Patients taking the drug, made by Novo Nordisk, should still new weight loss pill a low-calorie diet and exercise regularly, the FDA noted. It works by stimulating insulin production and triggering the release of glucagon a hormone produced by the body from the pancreas.
The drug also dampens appetite. Saxenda should not be used with any other drugs in this class, including Victoza — a treatment for type 2 diabetes. Saxenda and Victoza contain the same active ingredient liraglutidebut Saxenda contains a larger dose of it. Three new fda approved weight loss pill trials assessed the safety and effectiveness of the drug for weight loss. The trials involved roughly 4, obese and overweight people with and without other weight-related conditions.
All of the participants were counseled about lifestyle changes, such as a low-calorie diet and regular exercise. One clinical trial that involved patients without diabetes found that patients taking Saxenda had an average weight loss of 4. Of the people treated with the drug, 62 percent lost at least 5 percent of their body weight. Meanwhile, only 34 percent of those given an inactive placebo had the same result. Another clinical trial that included patients with type 2 diabetes found that patients had an average weight loss of almost 4 percent after one year.
Of those given Saxenda, 49 percent lost at least 5 percent of their body weight, compared to 16 percent of those who were given a placebo treatment. The FDA added that patients should be examined to determine if Saxenda is working after 16 weeks of treatment. Those who do not lose at least 4 percent of their body weight by that time should stop taking the medication, the FDA said. The most common side effects associated with Saxenda included nausea, diarrhea, constipation, vomiting, low blood sugar and loss of appetite.
Other more serious side effects can include pancreatitis infection of the pancreasgallbladder disease, lowered kidney function, suicidal thoughts and increased heart rate, the agency noted. Patients who experience a prolonged increase in their resting heart rate should stop taking Saxenda, the FDA added. Tumors of the thyroid gland were associated with Saxenda treatment in rodent studies. It is unclear, however, if the drug causes thyroid tumors, including a type of thyroid cancer called medullary thyroid carcinoma MTCin humans.
Patients who have been diagnosed with MTC or have a family history of the condition should not take Saxenda. Patients with a condition known as multiple endocrine neoplasia syndrome type 2, which increases the risk for MTC, should also not take Saxenda, the agency said. The FDA has also required that additional studies involving Saxenda investigate the safety and effectiveness of the drug in children, including how it could affect growth and development. The FDA also required that an MTC case registry be established to identify any possible increase in cases associated with Saxenda use over a minimum of 15 years.
Ongoing clinical trials are also examining the possible risk of breast cancer associated with Saxenda. This material may new weight loss pill be buy pure natural forskolin, broadcast, rewritten, or redistributed. Replay: News At Noon. News Channel 3 TV Schedule. Your Voice Your Vote. Posted am, January 12,by George Brown and CBS News Wire.
Facebook Twitter Reddit Pinterest LinkedIn Email. This new fda approved weight loss pill an archived article and the information in the article may new fda approved weight loss pill outdated. Please look at the time stamp on the story to see when it was last updated. Facebook Twitter Reddit Pinterest LinkedIn Email. Half off or more from local restaurants, services, and other businesses. News On-Air Seen on TV. Mobile Apps Android App. Severe Weather iPad App. Notice: You're using an outdated version of Internet Explorer.
For the best experience please upgrade your browser. Send to Email Address.
New Years Resolutions and FDA Approved Weight Loss Drugs
Information and resources for prescribing LIVALO. Feb 04, · the first weight loss treatment device The U.S. Food and Drug Administration today approved the Maestro FDA News Release. FDA approves. alli® Can Help Prevent About 25% of Fat You Eat From Getting Absorbed!.